Every letter we have printed

The published pharmacokinetic parameters are derived from the approved formulations, and nothing establishes that material of unknown formulation behaves the same way. Excipients and concentration both affect absorption for compounds of this kind.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

I would rather see no badge and a link reading "eleven reports, most recent April" than any mark currently in circulation. It is duller and it tells the reader the two things they actually need.

A badge is a statement about a moment. It says a sample submitted on a particular day met a particular threshold, and it is displayed indefinitely on a page selling material made months later. Nothing dishonest has happened and the reader has still been told something untrue.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

Hand hygiene before anything else is the single highest-yield step in every published account of technique in any setting, and it is the step most often skipped because it is the least visible.

Single-use means single-use, and the reason is mechanical as much as microbiological. A needle blunts on first insertion, and the second insertion is measurably rougher. This is one of the few places where the practical argument and the aseptic argument agree completely.

In-use stability is a property of a preparation and everything published is about a powder. The moment a vial is reconstituted it becomes a different material with a different shelf life, and the certificate that came with it has nothing to say about that.

Concentration matters for solution stability and it is chosen by the person reconstituting rather than by anybody who has studied it. A dilute preparation and a concentrated one are two different experiments, and both are described by the same anecdote.

Single-use indicators are much better than nothing and much weaker than a logger, because they tell you a threshold was crossed and not for how long. Ten minutes above eight degrees on a loading bay and eleven hours in a hot van produce the same red mark.

Buyers ask for what they have seen other buyers ask for. Where nobody has ever seen a report of a particular kind, demand for it cannot form, and the absence is self-sustaining.

Comparison shopping in this market is conducted on price and purity, in that order, and both are single numbers. A market that compares on two scalars will not develop a third.

A point from the inspection side. Terminal sterilisation, where the product tolerates it, is a different and stronger proposition than aseptic processing, and peptides generally do not tolerate it. That is the real reason this whole subject is difficult, and it is a chemistry constraint rather than a corporate one.

You keep saying you are criticising documentation and not honesty. I think that distinction is doing more work than it can bear. If a company knows buyers read a purity certificate as a safety document and issues one anyway, the omission is doing something.

Your list of what you asked suppliers for is the right list and I would add one item: the environmental monitoring trend rather than a single result. A trend shows whether a suite is under control; one plate shows what happened on one day.

The most useful outcome of this series for me has been the vocabulary. I can now ask a supplier a question that is specific enough to have an answer, which was not true a year ago, and specific questions get answered far more often than general ones.

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.

Peptides frequently interfere with the amoebocyte lysate assay, and the interference can go in either direction. A laboratory that has not performed and reported the inhibition and enhancement study has produced a number of unknown validity, and that study is a routine part of the method.

Storage becomes a maintenance problem at scale. Somebody holding a year of supply has a stability question that somebody holding a month does not, and the practical literature is written almost entirely for the second case.

Your piece treats maintenance as a single question. In the accounts I read there are at least three: maintaining a weight, maintaining a metabolic marker and maintaining a behaviour. They come apart in practice and are almost always discussed together.

The most honest account I have read simply said the person could not remember deciding. That is a real answer and there is nowhere to record it, so it becomes a missing value.

Timing matters as much as reason. Stopping in week three and stopping in year three are different events with different consequences, and reporting a single discontinuation rate for a study collapses that entirely.

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

The commercial literature describes maintenance as a phase; the trial literature describes it as an extension arm; the people I correspond with describe it as the rest of their life. Three timescales, one word, and most confusion in this area comes from the mismatch.

There is a selection effect in every maintenance dataset. The people still in the study at month thirty are the people for whom it worked, and any statement about maintenance derived from them describes that subgroup rather than the original population.

Your fortnightly arithmetic table is correct but I think it understates the practical point. A fourfold peak-to-trough swing is not merely lower average exposure; it is a different drug experience, with the last few days of each cycle spent at a concentration the person has effectively titrated off.

The distinction between stopping and pausing is made by the person and not by the data. Somebody who intends to resume is recorded as a discontinuation, and the two populations behave very differently afterwards.

I came to this department sceptical of the whole enterprise and I have stayed for three years. The scepticism has survived and it now has better material to work with.

Escalation schedules in the published trials were chosen for study logistics as much as for tolerability, and they have since been read as optimal. There is very little published work comparing schedules head to head.

Symptoms at a first dose and symptoms after a step up are different signals, and grouping them loses information. The first tells you about the molecule and the second tells you about the increment.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

Duration of follow-up drives incidence mechanically: a longer study finds more of everything. Comparing rates between studies of different lengths without annualising is a category error and it is done constantly.

Any strategy described in this context should be labelled with what supports it: a trial, an observational study, professional guidance, or nothing but practice. Four labels, applied honestly, would change how the whole subject reads.

Agitation matters. A vial carried in a bag for a day has experienced mechanical stress that a vial on a shelf has not, and interfacial stress is a recognised cause of aggregation in protein preparations generally.

Adsorption to the container is under-appreciated. At low concentrations a meaningful fraction of peptide can be lost to the glass or the plastic within hours, which looks exactly like degradation and is not. It is also the reason a dilute working solution behaves worse than a concentrated one.

Speaking as a broker: customs holds are the excursion risk nobody budgets for, and they are not rare. A pack qualified for seventy-two hours meets a four-day inspection queue and there is no mechanism by which anybody is told. The paperwork problem and the temperature problem are the same problem.

Estimated glomerular filtration rate is calculated from creatinine, so everything that moves creatinine moves the estimate. During substantial change in body composition the equation is being applied outside the conditions in which it was derived, and the estimate carries more uncertainty than the single number suggests.

Trend beats absolute value for almost everything in an organ panel, and a single report cannot show a trend. The most useful thing anybody can do is keep every result they have ever had in one place.

Water is the usual source and glassware is the usual carrier. Depyrogenation of the container by dry heat is the step that gets skipped in small operations, because it looks like a detail and it is the difference between a clean result and a puzzling one.

The test is inexpensive, it is available from ordinary contract laboratories, and it requires a small quantity of material. There is no technical reason it is absent from this trade and every commercial one.